v3.26.1
SEGMENT REPORTING
 3 Months Ended
Mar. 31, 2026
Segment Reporting [Abstract]  
SEGMENT REPORTING SEGMENT REPORTING
The following table presents segment revenue and significant segment expenses (in thousands) for the three months ended March 31, 2026 and 2025:
THREE MONTHS ENDED MARCH 31,
20262025
REVENUE:
Total segment revenue367 211,246 
LESS:
Rinvatercept program expenses(2,650)(1,517)
Elritercept program expenses(3)(18,895)
Cibotercept program expenses324 (5,908)
Preclinical & development expenses(2,006)(1,744)
Compensation costs (excluding stock based compensation)(8,190)(13,777)
Other external costs(7,047)(7,796)
Other segment items1(4,503)(13,158)
Net income (loss)(23,708)148,451 

The Company manages operations on a consolidated basis as a single reportable and single operating segment focused on developing novel therapeutics. Segment revenue above is 100 percent attributed to the Company’s agreements with Takeda and Hansoh and is equal to consolidated total revenue. All revenues are derived in the United States where the agreements originated. The Company manages expenses on a program level. The significant expense categories outlined above align with the segment-level information that is regularly provided to the chief operating decision maker (“CODM”) to allocate resources, assess performance of the reportable segment, and make key operating decisions. On a quarterly basis, the Company's CODM, who is its Chief Executive Officer, reviews financial information, including consolidated net income, clinical expenses by program, other company expenses and a long-range cash flow projection, to make resource decisions for the Company’s programs to achieve the approved corporate goals. No segment asset information is provided above as the CODM is focused on how expenses impact ending cash by period and overall cash runway. Any review of segment assets, which would focus on cash and cash equivalents, would be at the same level as the consolidated balance sheet. All long-lived assets are held in the United States.